Compare Intel Corp (INTC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Intel (INTC) trades at $98.12, down 3.19% today, amid mixed technical signals with bearish moving averages but bullish oscillators. Fundamentally, the company shows improving operational trends with three consecutive quarterly EPS beats and positive operating cash flow of $9.70B in 2025, though net income remains negative at -$267M. The stock has surged over 220% year-to-date as investors assess the progress of Intel's foundry turnaround strategy and High-NA chipmaking advancements.

Intel presents a high-risk, high-reward opportunity as the company executes its strategic pivot to a foundry model. While valuation metrics appear stretched with a P/E of 904, analyst consensus targets $111.72 suggesting 14% upside potential. Key risks include intense competition from TSMC and AMD, ongoing negative profitability, and the execution challenges of the foundry transition in a capital-intensive industry.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.